Kairos Pharma (KAPA) Institutional Ownership $1.26 +0.08 (+6.78%) As of 04:10 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartHeadlinesOwnershipSEC FilingsBuy This Stock Institutional Ownership Changes (13F Filings) for Kairos Pharma (NYSEAMERICAN:KAPA)Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$1.36MNumber ofInstitutional Sellers(last 12 months)0 Get KAPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Kairos Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Kairos Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/12/2025 XTX Topco Ltd62,746$44K0.0%N/A0.307% 5/15/2025 Armistice Capital LLC1,404,000$1.31M0.0%N/A10.248% (Data available from 1/1/2016 forward) KAPA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KAPA shares? During the previous two years, the following institutional investors and hedge funds held shares of Kairos Pharma shares: Armistice Capital LLC ($1.31M), XTX Topco Ltd ($44K).Learn more on Kairos Pharma's institutional investors. Which institutional investors have been buying Kairos Pharma's stock? The following institutional investors have purchased Kairos Pharma's stock in the last 24 months: Armistice Capital LLC ($1.40M), and XTX Topco Ltd ($62.75K). How much institutional buying is happening at Kairos Pharma? Institutional investors have bought a total of 1,466,746 shares in the last 24 months. This purchase volume represents approximately $1.36M in transactions. Related Companies Armata Pharmaceuticals Institutional Ownership ESSA Pharma Institutional Ownership Immunic Institutional Ownership Milestone Pharmaceuticals Institutional Ownership Elutia Institutional Ownership OKYO Pharma Institutional Ownership Pliant Therapeutics Institutional Ownership Entera Bio Institutional Ownership Celularity Institutional Ownership Quince Therapeutics Institutional Ownership This page (NYSEAMERICAN:KAPA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kairos Pharma, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kairos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access